Loading...

Koninklijke Philips N.V. Peer Comparison

Metric Value Ranking
Market Cap $26.3 Billion 6/20 ABT
$226.3B
BSX
$155.9B
SYK
$147.0B
MDT
$117.1B
EW
$44.7B
PHG
$26.3B
STE
$21.5B
ZBH
$19.7B
PODD
$19.6B
GMED
$11.4B
BIO
$8.8B
GKOS
$7.9B
BRKR
$7.8B
INSP
$5.6B
NARI
$4.7B
ITGR
$4.6B
NVCR
$2.3B
NUVA
$2.1B
CNMD
$1.9B
ZIMV
$361.3M
Gross Margin 46% 17/20 PODD
100%
ZIMV
95%
NARI
87%
INSP
84%
EW
81%
GKOS
77%
NVCR
77%
NUVA
72%
BSX
69%
MDT
65%
SYK
65%
GMED
57%
CNMD
57%
ABT
56%
BIO
55%
BRKR
47%
PHG
46%
STE
44%
ITGR
16%
ZBH
0%
Profit Margin 4% 14/20 EW
100%
BIO
100%
PODD
21%
ABT
15%
MDT
15%
CNMD
15%
BSX
11%
STE
11%
INSP
9%
SYK
8%
GMED
8%
BRKR
5%
ITGR
5%
PHG
4%
NUVA
2%
ZBH
0%
ZIMV
-4%
NARI
-12%
NVCR
-20%
GKOS
-22%
EBITDA margin 8% 10/20 BIO
214%
EW
30%
PODD
24%
CNMD
21%
NUVA
19%
BSX
18%
ABT
18%
STE
17%
SYK
9%
PHG
8%
GMED
8%
ITGR
8%
INSP
7%
MDT
0%
ZIMV
-3%
NARI
-5%
BRKR
-9%
NVCR
-21%
GKOS
-26%
ZBH
-100%
Quarterly Revenue $4.8 Billion 4/20 ABT
$10.6B
MDT
$8.4B
SYK
$6.4B
PHG
$4.8B
BSX
$4.2B
EW
$1.4B
STE
$1.3B
BRKR
$864.4M
ITGR
$746.3M
BIO
$649.7M
GMED
$625.7M
PODD
$372.6M
NUVA
$317.8M
CNMD
$316.7M
INSP
$203.2M
NVCR
$155.1M
NARI
$153.4M
ZIMV
$103.2M
GKOS
$96.7M
ZBH
$0
Quarterly Earnings $198.9 Million 7/20 EW
$3.1B
ABT
$1.6B
MDT
$1.3B
BIO
$653.2M
SYK
$546.0M
BSX
$468.0M
PHG
$198.9M
STE
$150.0M
PODD
$77.5M
GMED
$51.8M
CNMD
$49.0M
BRKR
$40.9M
ITGR
$35.4M
INSP
$18.5M
NUVA
$7.4M
ZBH
-$0
ZIMV
-$4.4M
NARI
-$18.4M
GKOS
-$21.4M
NVCR
-$30.6M
Quarterly Free Cash Flow $301.1 Million 3/20 MDT
$554.0M
EW
$319.9M
PHG
$301.1M
BIO
$246.7M
GMED
$161.7M
STE
$148.8M
ITGR
$131.8M
PODD
$76.1M
CNMD
$47.8M
INSP
$44.3M
BRKR
$5.8M
ZIMV
$4.6M
ABT
-$0
NVCR
-$307,000
NUVA
-$495,000
NARI
-$995,000
GKOS
-$11.0M
BSX
-$1.1T
ZBH
-$0
SYK
-$0
Trailing 4 Quarters Revenue $19.8 Billion 5/20 BIO
$2.7T
ABT
$41.2B
MDT
$33.0B
SYK
$22.6B
PHG
$19.8B
BSX
$15.9B
EW
$5.9B
ZBH
$5.7B
STE
$5.4B
BRKR
$3.2B
GMED
$2.5B
ITGR
$2.0B
PODD
$1.8B
CNMD
$1.3B
NUVA
$1.2B
INSP
$755.6M
NVCR
$577.7M
NARI
$574.5M
ZIMV
$451.3M
GKOS
$360.3M
Trailing 4 Quarters Earnings -$515.4 Million 19/20 ABT
$10.6B
MDT
$8.4B
SYK
$6.4B
PHG
$4.8B
BSX
$4.2B
EW
$1.4B
STE
$1.3B
BRKR
$864.4M
ITGR
$746.3M
BIO
$649.7M
GMED
$625.7M
PODD
$372.6M
NUVA
$317.8M
CNMD
$316.7M
INSP
$203.2M
NVCR
$155.1M
NARI
$153.4M
ZIMV
$103.2M
GKOS
$96.7M
ZBH
-$0
Quarterly Earnings Growth 106% 7/20 GMED
5094%
NUVA
925%
EW
698%
BIO
515%
INSP
317%
CNMD
209%
PHG
106%
PODD
49%
MDT
40%
NVCR
38%
GKOS
30%
STE
30%
ITGR
30%
ABT
15%
ZIMV
13%
ZBH
0%
BSX
-7%
SYK
-52%
BRKR
-54%
NARI
-681%
Annual Earnings Growth -254% 18/20 EW
218%
PODD
215%
INSP
174%
CNMD
131%
ZIMV
58%
BSX
36%
ZBH
36%
NVCR
32%
MDT
31%
BRKR
18%
ITGR
15%
ABT
4%
SYK
-7%
STE
-11%
GKOS
-16%
GMED
-47%
NUVA
-50%
PHG
-254%
NARI
-934%
BIO
-18757%
Quarterly Revenue Growth -2% 16/20 GMED
63%
INSP
33%
GKOS
24%
NVCR
22%
NARI
21%
BSX
19%
BRKR
16%
SYK
11%
ITGR
6%
ABT
5%
MDT
5%
CNMD
4%
BIO
3%
NUVA
2%
STE
-1%
PHG
-2%
EW
-9%
PODD
-14%
ZIMV
-49%
ZBH
-100%
Annual Revenue Growth 1% 18/20 BIO
99740%
GMED
97%
INSP
25%
NARI
19%
BRKR
16%
NVCR
14%
GKOS
13%
PODD
12%
BSX
11%
SYK
10%
MDT
6%
ITGR
6%
ZBH
4%
NUVA
4%
STE
4%
ABT
3%
CNMD
2%
PHG
1%
EW
-3%
ZIMV
-49%
Cash On Hand $2.0 Billion 4/20 EW
$3.7B
SYK
$3.7B
BSX
$2.5B
PHG
$2.0B
MDT
$1.4B
PODD
$902.6M
GMED
$622.8M
ZBH
$525.5M
BIO
$410.4M
STE
$172.2M
BRKR
$148.1M
INSP
$147.5M
GKOS
$100.1M
NUVA
$80.7M
ZIMV
$66.8M
NARI
$41.1M
CNMD
$38.5M
ITGR
$35.6M
ABT
-$0
NVCR
-$0
Short Term Debt $0 18/20 SYK
$12.2B
MDT
$3.7B
BSX
$1.7B
ZBH
$863.0M
NUVA
$360.8M
NVCR
$86.4M
STE
$80.0M
PODD
$42.0M
BRKR
$32.8M
EW
$24.2M
ITGR
$13.9M
GMED
$11.0M
ZIMV
$4.4M
NARI
$1.6M
BIO
$1.3M
CNMD
$717,000
INSP
$109,000
PHG
-$0
ABT
-$0
GKOS
-$0
Long Term Debt $0 17/20 MDT
$24.6B
BSX
$9.2B
ZBH
$5.3B
STE
$2.3B
BRKR
$2.3B
PODD
$1.4B
BIO
$1.2B
ITGR
$1.2B
CNMD
$940.1M
EW
$682.5M
NUVA
$545.4M
GMED
$523.5M
ZIMV
$220.3M
GKOS
$157.1M
NARI
$31.1M
INSP
$25.2M
PHG
$0
ABT
$0
SYK
$0
NVCR
$0
PE -1.00 15/20 INSP
169.57
GMED
125.00
BSX
87.14
NUVA
73.28
STE
49.51
SYK
49.12
PODD
46.59
ITGR
40.57
ABT
39.25
ZBH
29.66
MDT
27.31
BRKR
25.68
CNMD
14.66
EW
10.75
PHG
-1.00
GKOS
-1.00
NVCR
-1.00
BIO
-1.00
NARI
-1.00
ZIMV
-1.00
PS 1.21 18/20 GKOS
21.98
PODD
10.82
BSX
9.80
NARI
8.15
EW
7.61
INSP
7.42
SYK
6.51
ABT
5.49
GMED
4.62
NVCR
4.00
STE
3.97
MDT
3.55
ZBH
3.48
BRKR
2.42
ITGR
2.29
NUVA
1.70
CNMD
1.50
PHG
1.21
ZIMV
0.80
BIO
0.00
PB 0.00 18/20 PODD
17.54
GKOS
11.85
NARI
10.77
INSP
8.05
BSX
7.44
EW
4.65
BRKR
4.25
SYK
3.42
STE
3.26
ITGR
2.84
GMED
2.81
MDT
2.40
NUVA
2.34
CNMD
2.07
ZBH
1.37
BIO
1.17
ZIMV
0.89
PHG
0.00
ABT
0.00
NVCR
0.00
PC 13.26 16/20 ITGR
129.50
STE
125.02
NARI
113.76
MDT
84.03
GKOS
79.09
BSX
62.30
BRKR
52.87
CNMD
50.19
SYK
40.25
INSP
37.99
ZBH
37.50
NUVA
25.83
PODD
21.72
BIO
21.35
GMED
18.37
PHG
13.26
EW
12.16
ZIMV
5.41
ABT
-1.00
NVCR
-1.00
Liabilities to Equity 0.00 18/20 NVCR
2.39
BRKR
2.34
PODD
1.71
CNMD
1.48
NUVA
1.34
ITGR
0.95
ZIMV
0.93
MDT
0.85
BSX
0.83
NARI
0.60
STE
0.55
ZBH
0.48
BIO
0.42
GKOS
0.39
EW
0.35
GMED
0.25
INSP
0.14
PHG
0.00
ABT
0.00
SYK
0.00
ROA -1.00 17/20 EW
32%
PODD
14%
SYK
7%
CNMD
6%
BSX
5%
MDT
5%
BRKR
5%
STE
4%
ITGR
4%
INSP
4%
ZBH
3%
GMED
2%
NUVA
1%
ZIMV
-4%
NARI
-11%
GKOS
-16%
PHG
-100%
ABT
-100%
NVCR
-100%
BIO
-6012%
ROE -0.04 14/20 EW
44%
PODD
38%
BRKR
17%
CNMD
14%
BSX
9%
MDT
9%
SYK
7%
STE
7%
ITGR
7%
ZBH
5%
INSP
5%
NUVA
3%
GMED
2%
PHG
-4%
ZIMV
-8%
NARI
-18%
GKOS
-22%
NVCR
-42%
ABT
-100%
BIO
-8513%
Current Ratio -1.00 18/20 INSP
7.99
GMED
5.00
EW
3.86
GKOS
3.59
BIO
3.40
ZBH
3.08
STE
2.82
NARI
2.66
BSX
2.22
MDT
2.18
ZIMV
2.08
ITGR
2.05
NUVA
1.75
CNMD
1.67
PODD
1.59
BRKR
1.43
NVCR
0.00
PHG
-1.00
ABT
-1.00
SYK
-1.00
Quick Ratio -1.00 18/20 INSP
169.57
GMED
125.00
BSX
87.14
NUVA
73.28
STE
49.51
SYK
49.12
PODD
46.59
ITGR
40.57
ABT
39.25
ZBH
29.66
MDT
27.31
BRKR
25.68
CNMD
14.66
EW
10.75
PHG
-1.00
GKOS
-1.00
NVCR
-1.00
BIO
-1.00
NARI
-1.00
ZIMV
-1.00
Long Term Debt to Equity 0.00 17/20 BRKR}
1.24
PODD}
1.21
CNMD}
1.01
ITGR}
0.71
NUVA}
0.61
ZIMV}
0.54
MDT}
0.51
BSX}
0.45
ZBH}
0.37
STE}
0.35
GKOS}
0.24
BIO}
0.16
GMED}
0.13
EW}
0.07
NARI}
0.07
INSP}
0.04
PHG}
0.00
SYK}
0.00
NVCR}
0.00
ABT}
-1.00
Debt to Equity 0.00 19/20 BRKR
1.26
PODD
1.25
NUVA
1.02
CNMD
1.01
ITGR
0.72
MDT
0.58
ZIMV
0.54
BSX
0.53
ZBH
0.43
STE
0.36
SYK
0.28
GKOS
0.24
NVCR
0.24
BIO
0.16
GMED
0.13
NARI
0.08
EW
0.07
INSP
0.04
PHG
0.00
ABT
-1.00
Burn Rate -9.08 18/20 BSX
7.96
ZIMV
4.66
GKOS
3.62
BRKR
2.56
ITGR
2.48
MDT
2.16
NARI
2.06
SYK
1.46
NUVA
0.77
ABT
0.00
NVCR
0.00
BIO
-0.68
ZBH
-1.00
EW
-1.21
CNMD
-3.43
STE
-4.48
INSP
-8.45
PHG
-9.08
GMED
-22.13
PODD
-70.80
Cash to Cap 0.08 2/20 ZIMV
0.18
PHG
0.08
EW
0.08
PODD
0.05
GMED
0.05
BIO
0.05
NUVA
0.04
ZBH
0.03
INSP
0.03
BSX
0.02
SYK
0.02
BRKR
0.02
CNMD
0.02
MDT
0.01
GKOS
0.01
STE
0.01
ITGR
0.01
NARI
0.01
ABT
0.00
NVCR
0.00
CCR 1.51 4/20 ITGR
3.72
GMED
3.12
INSP
2.39
PHG
1.51
STE
0.99
PODD
0.98
CNMD
0.98
GKOS
0.52
MDT
0.44
BIO
0.38
BRKR
0.14
EW
0.10
NARI
0.05
NVCR
0.01
ABT
0.00
NUVA
-0.07
ZIMV
-1.04
BSX
-2442.82
ZBH
SYK
EV to EBITDA 77.29 10/20 INSP}
382.86
SYK}
267.72
GMED}
236.00
PODD}
228.20
BSX}
219.91
ABT}
116.66
STE}
108.00
EW}
103.65
ITGR}
98.99
PHG}
77.29
NUVA}
47.54
CNMD}
43.12
BIO}
6.87
ZBH}
-1.00
NVCR}
-74.74
BRKR}
-129.77
ZIMV}
-168.88
GKOS}
-323.48
NARI}
-647.99
MDT}
-4237.33
EV to Revenue 1.37 17/20 GKOS
22.14
PODD
11.09
BSX
10.32
NARI
8.13
INSP
7.25
EW
7.11
SYK
6.88
ABT
5.49
GMED
4.58
MDT
4.37
STE
4.37
NVCR
4.15
BRKR
3.08
ITGR
2.86
NUVA
2.37
CNMD
2.20
PHG
1.37
ZIMV
1.14
BIO
0.00
ZBH
-1.00